Section Arrow
Quote
BDRX.NASDAQ
- Biodexa Pharmaceuticals plc
Quotes are at least 15-min delayed:2025/07/14 05:35 EDT
Pre Market
Last
 0.851
-0.023 (-2.63%)
Bid
0.8505
Ask
0.862
High 0.862 
Low 0.85 
Volume 1749 
Regular Hours
Last
 0.874
-0.0155 (-1.74%)
Day High 
0.89 
Prev. Close
0.8895 
1-M High
1.29 
Volume 
154.94K 
Bid
0.8505
Ask
0.862
Day Low
0.86 
Open
0.8727 
1-M Low
0.7846 
Market Cap 
4.49M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.88 
20-SMA 0.93 
50-SMA 1.13 
52-W High 30 
52-W Low 0.7846 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-10.00/-0.41
Enterprise Value
4.61M
Balance Sheet
Book Value Per Share
2.24
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.13
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0502-0.0095-15.91%-- 
Pre Market 0.0523 +0.0021 +4.18%
INKTMiNK Therapeutics Inc64.17+56.44+730.14%-- 
Pre Market 43.62 -20.55 -32.02%
RXRXRecursion Pharmaceuticals5.28-0.435-7.61%-- 
Pre Market 5.27 -0.01 -0.19%
CVMCel-Sci Corp3.53-0.29-7.59%-- 
Pre Market 3.07 -0.46 -13.03%
MISTMilestone Pharmaceuticals1.56-1-39.06%-- 
Pre Market 1.58 +0.02 +1.28%
Quotes are at least 15-min delayed：2025/07/14 05:35 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasivebladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.